{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:07:38Z","timestamp":1789877258620,"version":"4.0.1"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>New scientific findings have recently shown that dasatinib (DAS), the first-choice oral drug in the treatment of chronic myeloid leukemia (CML) for adult patients who are resistant or intolerant to imatinib, is also potentially useful in the paediatric age. Moreover, recent preclinical evidences suggest that this drug could be useful for the treatment of Duchenne muscular dystrophy, since it targets cSrc tyrosin kinase. Based on these considerations, the purpose of this work was to use the strategy of complexation with hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CD) in order to obtain an aqueous preparation of DAS, which is characterized by a low water solubility (6.49 \u00d7 10\u22124 mg\/mL). Complexation studies demonstrated that HP-\u03b2-CD is able to form a stable host-guest inclusion complex with DAS with a 1:1 apparent formation constant of 922.13 M\u22121, as also demonstrated by the Job\u2019s plot, with an increase in DAS aqueous solubility of about 21 times in the presence of 6% w\/v of HP-\u03b2-CD (0.014 mg\/mL). The inclusion complex has been prepared in the solid state by lyophilization and characterized by Fourier Transform Infrared (FT-IR), Nuclear Magnetic Resonance (NMR), Differential Scanning Calorimetry (DSC) techniques, and its dissolution profile was studied at different pH values. Moreover, in view of potential use of DAS for Duchenne muscular dystrophy, the cytotoxic effect of the inclusion complex has been assessed on C2C12 cells, a murine muscle satellite cell line. In parallel, a one-week oral treatment was performed in wild type C57Bl\/6J mice to test both palatability and the exposure levels of the new oral formulation of the compound. In conclusion, this new inclusion complex could allow the development of a liquid and solvent free formulation to be administered both orally and parenterally, especially in the case of an administration in paediatric age.<\/jats:p>","DOI":"10.3390\/ijms20030591","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T10:58:27Z","timestamp":1548845907000},"page":"591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Dasatinib\/HP-\u03b2-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders"],"prefix":"10.3390","volume":"20","author":[{"given":"Annalisa","family":"Cutrignelli","sequence":"first","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sanarica","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"},{"name":"Unity of Pharmacology, Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopalco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lopedota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-638X","authenticated-orcid":false,"given":"Valentino","family":"Laquintana","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Franco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Boccanegra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"},{"name":"Unity of Pharmacology, Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6339-2222","authenticated-orcid":false,"given":"Paola","family":"Mantuano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"},{"name":"Unity of Pharmacology, Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"},{"name":"Unity of Pharmacology, Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Denora","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)\u2013piperazin-1-yl]-2\u2013methylpyrimidin-4-ylamino] thiazole 5\u2013carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"Melville, N.A. (2017, January 22\u201325). Dasatinib in Children: An Effective Alternative to Imatinib. Proceedings of the European Hematology Association (EHA) 2017 Congress, Madrid, Spain."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","article-title":"Dasatinib in Children and Adolescent With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the innovative Therapies for Children With Cancer Consortium","volume":"31","author":"Zwaan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1083\/jcb.200905048","article-title":"Dystrophin is a microtubule-associated protein","volume":"186","author":"Prins","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0165-6147(00)01770-3","article-title":"Molecular pathophysiology and targeted therapeutics for muscular dystrophy","volume":"22","author":"Hoffman","year":"2001","journal-title":"Trends Pharm. Sci."},{"key":"ref_8","first-page":"40","article-title":"Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: An overview","volume":"31","year":"2012","journal-title":"Acta Myol. Myopathies Cardiomyopathies Off. J. Mediterr. Soc. Myol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddu287","article-title":"Gene expression in mdx mouse muscle in relation to age and exercise: Aberrant mechanical-metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy","volume":"23","author":"Camerino","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.3390\/ijms14023683","article-title":"NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicity","volume":"14","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/hmg\/ddv469","article-title":"Dasatinib as a treatment for Duchenne muscular dystrophy","volume":"25","author":"Lipscomb","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejps.2018.11.013","article-title":"Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate","volume":"127","author":"Lopalco","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_13","unstructured":"Korashy, H.M., Rahman, A.F.M.M., and Kassem, G.M. (2012). \u00abDasatinib\u00bb in Profiles of Drug Substances, Excipients, and Related Methodology, Academic Press."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1002\/jps.24200","article-title":"A new complex of curcumin with sulfobutylether-\u03b2-cyclodextrin: Characterization studies and in vitro evaluation of cytotoxic and antioxidant activity on HepG-2 cells","volume":"103","author":"Cutrignelli","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/jps.23900","article-title":"Characterization and release studies of liposomal gels containing glutathione\/cyclodextrins complexes potentially useful for cutaneous administration","volume":"103","author":"Cutrignelli","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10847-006-9229-4","article-title":"Effect of cyclodextrins on physico-chemical and release properties of Eudragit RS 100 microparticles containing glutathione","volume":"57","author":"Lopedota","year":"2007","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpb.2017.10.015","article-title":"Characterization of minoxidil\/hydroxypropyl-\u03b2-cyclodextrin inclusion complex in aqueous alginate gel useful for alopecia management: Efficacy evaluation in male rat","volume":"122","author":"Tricarico","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.xphs.2017.11.016","article-title":"Alginate-Based Hydrogel Containing Minoxidil\/Hydroxypropyl-\u03b2-Cyclodextrin Inclusion Complex for Topical Alopecia Treatment","volume":"107","author":"Lopedota","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3109\/03639045.2014.900078","article-title":"New ethanol and propylene glycol free gel formulations containing a minoxidil-methyl-\u03b2-cyclodextrin complex as promising tools for alopecia treatment","volume":"41","author":"Lopedota","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_21","first-page":"117","article-title":"Phase solubility techniques","volume":"4","author":"Higuchi","year":"1965","journal-title":"Adv. Anal. Chem. Instrum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2006.02.006","article-title":"Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin","volume":"314","author":"Ventura","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_23","unstructured":"Purohit, P., Rampalli, S., Murali, M.S.V., Upalla, L., and Pothana, P. (2015). Process for Preparing Dasatinib Monohydrate. (No 9,145.406 B2), U.S. Patent."},{"key":"ref_24","unstructured":"Yan, R., Yang, H., and Xu, Y. (2012). Polymorphs of Dasatinib, Preparation Methods and Pharmaceutical Composition Thereof. (No 2012\/0309968 A1), U.S. Patent."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","article-title":"Metabolism considerations for kinase inhibitors in cancer treatment","volume":"6","author":"Duckett","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rao, S., Larroque-Lombard, A.L., Peyrard, L., Thauvin, C., Rachid, Z., Williams, C., and Jean-Claude, B.J. (2015). Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: The concept of type III combi-targeting. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117215"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11010-017-2991-3","article-title":"Carnosine modulates nitric oxide in stimulated murine RAW 264.7 macrophages","volume":"431","author":"Caruso","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.xphs.2016.03.041","article-title":"Effect of Molecular Structure on the Relative Hydrogen Peroxide Scavenging Ability of Some \u03b1-Keto Carboxylic Acids","volume":"105","author":"Lopalco","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/jps.24653","article-title":"Mechanism of Decarboxylation of Pyruvic Acid in the Presence of Hydrogen Peroxide","volume":"105","author":"Lopalco","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/jps.24539","article-title":"Determination of pKa and Hydration Constants for a Series of \u03b1-Keto-Carboxylic Acids Using Nuclear Magnetic Resonance Spectrometry","volume":"105","author":"Lopalco","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/ml5000788","article-title":"Synthesis, characterization, and in vitro evaluation of a new TSPO-selective bifunctional chelate ligand","volume":"5","author":"Denora","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijpharm.2008.02.018","article-title":"Relationship between dissolution efficiency of Oxazepam\/carrier blends and drug and carrier molecular descriptors using multivariate regression analysis","volume":"358","author":"Cutrignelli","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s11095-016-1956-7","article-title":"Spray Dried Chitosan Microparticles for Intravesical Delivery of Celecoxib: Preparation and Characterization","volume":"33","author":"Lopedota","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1387-2656(05)11004-7","article-title":"Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction","volume":"11","author":"Berridge","year":"2005","journal-title":"Biotechnol. Annu. Rev."},{"key":"ref_35","first-page":"659","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Nihal","year":"2008","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_36","first-page":"1025","article-title":"Ryanodine channel complex stabilizer compound S48168\/ARM210 as a disease modifier in dystrophin-deficient mdx mice: Proof-of-concept study and independent validation of efficacy","volume":"32","author":"Capogrosso","year":"2018","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:29:38Z","timestamp":1760185778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["ijms20030591"],"URL":"https:\/\/doi.org\/10.3390\/ijms20030591","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]}}}